UnknownPhase 2NCT00722930
Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas
- Principal Investigator
- Mariano Provencio, MDClínica Puerta de Hierro
- Intervention
- Y90 Ibritumomab Tiuxetan(drug)
- Enrollment
- 38 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2008 – 2013
Study locations (11)
- Hospital Virgen de las Nieves, Granada, Granada, Spain
- Clinia Puerta de Hierro, Madrid, Madrid, Spain
- Clínica Ruber Internacional, Madrid, Madrid, Spain
- Hospital Virgen de la Victoria, Málaga, Malaga, Spain
- Complejo Hospitalario de Pontevedra, Pontevedra, Pontevedra, Spain
- Instituto Oncológico San Sebastián, Donostia / San Sebastian, San Sebastián, Spain
- Hospital Universitario de Canarias, San Cristóbal de La Laguna, Santa Cruz de Tenerife, Spain
- Hospital Universitario Virgen Macarena, Seville, Sevilla, Spain
- Hospital Sant Joan de Reus, Reus, Tarragona, Spain
- Hospital Virgen de la Salud de Toledo, Toledo, Toledo, Spain
- Hospital Universitario La Fe, Valencia, Valencia, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00722930 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGNANCT07126678Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular LymphomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGEARLY PHASE1NCT06976437A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsYANRU WANG
- RECRUITINGNCT06794268A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
- RECRUITINGPHASE1NCT07093073Clinical Study of U01（ssCART-19） in Patients With B-Cell LymphomaShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- RECRUITINGPHASE2NCT06959732Zanubrutinib Combined With G-CVP in Previously Untreated FLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEARLY PHASE1NCT06662227Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsWondercel Biotech (ShenZhen)
- RECRUITINGPHASE3NCT06549595A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsAstraZeneca